Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Liabilities (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Total Liabilities for 15 consecutive years, with $75.9 million as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities fell 14.74% year-over-year to $75.9 million; the TTM value through Mar 2026 reached $75.9 million, down 14.74%, while the annual FY2025 figure was $104.1 million, 14.83% down from the prior year.
  • Total Liabilities hit $75.9 million in Q1 2026 for Agios Pharmaceuticals, down from $104.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $165.1 million in Q3 2024 and bottomed at $75.9 million in Q1 2026.
  • Average Total Liabilities over 5 years is $116.8 million, with a median of $120.4 million recorded in 2023.
  • Year-over-year, Total Liabilities soared 37.13% in 2024 and then tumbled 38.61% in 2025.
  • Agios Pharmaceuticals' Total Liabilities stood at $137.9 million in 2022, then dropped by 8.56% to $126.1 million in 2023, then dropped by 3.06% to $122.2 million in 2024, then fell by 14.83% to $104.1 million in 2025, then dropped by 27.12% to $75.9 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $75.9 million, $104.1 million, and $101.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.